Abstract: A device for the exposure of blood to light produces a controlled, safe, and rapid exposure of blood to specific emissions, thereby inducing improved immune response. The device exposes the blood through a simplified macro blood flow path in which the internal or micro blood flow is in a spiral motion. The device includes a blood flow path, a pump, an exposure chamber, an ultraviolet light source, and a vacuum chamber.

Abstract: The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to HIV fusion protein. The present invention contemplates three categories of embodiments: protein or protein fragments, messenger RNA, or DNA/RNA. DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.

Abstract: The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one binding site of Cyclophilin A on the HIV capsid protein. (SEQ ID NOS: 2, 4, and 6) The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NOS: 2, 4, and 6), messenger RNA, or DNA/RNA. DNA/RNA compositions (SEQ ID NOS 1, 3, 5, 7, 9, and 11) may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.

Abstract: An immunogenic composition able to provide an immune response to Human Complement Factor H binding on one or more HIV glycoproteins is disclosed, which is characterized by at least one binding site epitope of the glycoproteins. Such immunogenic composition wherein the glycoprotein comprises gp120, gp41, or both glycoproteins gp120 and gp41 is hereby disclosed. Sialic acid is removed to enhance immune recognition of the composition and to impair Factor H binding. A medication having an inhibitive action on autoimmune response by specific inhibition of the cleavage of C3b by Factor H into inactive cell fragments.

Abstract: An antigenic and immunogenic composition of predetermined inactivated strains of human immunodeficiency virus (HIV) is disclosed. Inactivation is through psoralen and ultraviolet radiation; the composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H. Determination of strains for inactivation may be though immunotherapeutic genotyping or probabilistic assessment of risk of exposure.

Abstract: The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or protein fragments, messenger RNA, or DNA/RNA. DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.